HRTX
HRTX
NASDAQ · Biotechnology

Heron Therapeutics Inc

$1.26
+0.05 (+4.13%)
As of Feb 8, 2:03 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 35.92M 36.22M 29.20M
Net Income -2,667,111 -2,507,722 -2,038,148
EPS
Profit Margin -7.4% -6.9% -7.0%
Rev Growth +9.6% +20.2% -6.2%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 79.45M 87.16M 81.85M
Total Equity 119.48M 118.11M 119.94M
D/E Ratio 0.67 0.74 0.68
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -3,319,751 -3,086,652 -2,725,751
Free Cash Flow -2,830,658 -2,753,402 -2,024,759